Selected research
Market Analysis & Forecast
Global Burosumab Market Analysis and Forecast 2026-2032
Market perspective
The global Burosumab market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Burosumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Burosumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Burosumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Burosumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global manufacturers of Burosumab include Ultragenyx and Kyowa Kirin Co.,Ltd. etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Burosumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Burosumab, also provides the sales of main regions and countries. Of the upcoming market potential for Burosumab, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Burosumab sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Burosumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Burosumab sales, projected growth trends, production technology, application and end-user industry.
Burosumab Segment by Company
Ultragenyx
Kyowa Kirin Co.,Ltd.
Burosumab Segment by Type
10mg/mL
20mg/mL
30mg/mL
Burosumab Segment by Application
Minor Patients Over 1 Year Old
Adult Patients
Burosumab Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Burosumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Burosumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Burosumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Burosumab in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Burosumab manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Burosumab sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 10mg/mL
- 20mg/mL
- 30mg/mL
Applications
- Minor Patients Over 1 Year Old
- Adult Patients
Companies covered
- Ultragenyx
- Kyowa Kirin Co.,Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Burosumab Market by Type
- 1.2.1 Global Burosumab Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 10mg/mL
- 1.2.3 20mg/mL
- 1.2.4 30mg/mL
- 1.3 Burosumab Market by Application
- 1.3.1 Global Burosumab Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Minor Patients Over 1 Year Old
- 1.3.3 Adult Patients
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Burosumab Market Dynamics
- 2.1 Burosumab Industry Trends
- 2.2 Burosumab Industry Drivers
- 2.3 Burosumab Industry Opportunities and Challenges
- 2.4 Burosumab Industry Restraints
3 Global Market Growth Prospects
- 3.1 Global Burosumab Revenue Estimates and Forecasts (2021-2032)
- 3.2 Global Burosumab Revenue by Region
- 3.2.1 Global Burosumab Revenue by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Burosumab Revenue by Region (2021-2026)
- 3.2.3 Global Burosumab Revenue by Region (2027-2032)
- 3.2.4 Global Burosumab Revenue Market Share by Region (2021-2032)
- 3.3 Global Burosumab Sales Estimates and Forecasts 2021-2032
- 3.4 Global Burosumab Sales by Region
- 3.4.1 Global Burosumab Sales by Region: 2021 VS 2025 VS 2032
- 3.4.2 Global Burosumab Sales by Region (2021-2026)
- 3.4.3 Global Burosumab Sales by Region (2027-2032)
- 3.4.4 Global Burosumab Sales Market Share by Region (2021-2032)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
- 4.1 Global Burosumab Revenue by Manufacturers
- 4.1.1 Global Burosumab Revenue by Manufacturers (2021-2026)
- 4.1.2 Global Burosumab Revenue Market Share by Manufacturers (2021-2026)
- 4.1.3 Global Burosumab Manufacturers Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Burosumab Sales by Manufacturers
- 4.2.1 Global Burosumab Sales by Manufacturers (2021-2026)
- 4.2.2 Global Burosumab Sales Market Share by Manufacturers (2021-2026)
- 4.2.3 Global Burosumab Manufacturers Sales Share Top 10 and Top 5 in 2025
- 4.3 Global Burosumab Sales Price by Manufacturers (2021-2026)
- 4.4 Global Burosumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026
- 4.5 Global Burosumab Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Burosumab Manufacturers, Product Type & Application
- 4.7 Global Burosumab Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Burosumab Market CR5 and HHI
- 4.8.2 2025 Burosumab Tier 1, Tier 2, and Tier 3
5 Burosumab Market by Type
- 5.1 Global Burosumab Revenue by Type
- 5.1.1 Global Burosumab Revenue by Type (2021 VS 2025 VS 2032)
- 5.1.2 Global Burosumab Revenue by Type (2021-2032) & (US$ Million)
- 5.1.3 Global Burosumab Revenue Market Share by Type (2021-2032)
- 5.2 Global Burosumab Sales by Type
- 5.2.1 Global Burosumab Sales by Type (2021 VS 2025 VS 2032)
- 5.2.2 Global Burosumab Sales by Type (2021-2032) & (K Units)
- 5.2.3 Global Burosumab Sales Market Share by Type (2021-2032)
- 5.3 Global Burosumab Price by Type
6 Burosumab Market by Application
- 6.1 Global Burosumab Revenue by Application
- 6.1.1 Global Burosumab Revenue by Application (2021 VS 2025 VS 2032)
- 6.1.2 Global Burosumab Revenue by Application (2021-2032) & (US$ Million)
- 6.1.3 Global Burosumab Revenue Market Share by Application (2021-2032)
- 6.2 Global Burosumab Sales by Application
- 6.2.1 Global Burosumab Sales by Application (2021 VS 2025 VS 2032)
- 6.2.2 Global Burosumab Sales by Application (2021-2032) & (K Units)
- 6.2.3 Global Burosumab Sales Market Share by Application (2021-2032)
- 6.3 Global Burosumab Price by Application
7 Company Profiles
- 7.1 Ultragenyx
- 7.1.1 Ultragenyx Company Information
- 7.1.2 Ultragenyx Business Overview
- 7.1.3 Ultragenyx Burosumab Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.1.4 Ultragenyx Burosumab Product Portfolio
- 7.1.5 Ultragenyx Recent Developments
- 7.2 Kyowa Kirin Co.,Ltd.
- 7.2.1 Kyowa Kirin Co.,Ltd. Company Information
- 7.2.2 Kyowa Kirin Co.,Ltd. Business Overview
- 7.2.3 Kyowa Kirin Co.,Ltd. Burosumab Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.2.4 Kyowa Kirin Co.,Ltd. Burosumab Product Portfolio
- 7.2.5 Kyowa Kirin Co.,Ltd. Recent Developments
8 North America
- 8.1 North America Burosumab Market Size by Type
- 8.1.1 North America Burosumab Revenue by Type (2021-2032)
- 8.1.2 North America Burosumab Sales by Type (2021-2032)
- 8.1.3 North America Burosumab Price by Type (2021-2032)
- 8.2 North America Burosumab Market Size by Application
- 8.2.1 North America Burosumab Revenue by Application (2021-2032)
- 8.2.2 North America Burosumab Sales by Application (2021-2032)
- 8.2.3 North America Burosumab Price by Application (2021-2032)
- 8.3 North America Burosumab Market Size by Country
- 8.3.1 North America Burosumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 8.3.2 North America Burosumab Sales by Country (2021 VS 2025 VS 2032)
- 8.3.3 North America Burosumab Price by Country (2021-2032)
- 8.3.4 United States
- 8.3.5 Canada
9 Europe
- 9.1 Europe Burosumab Market Size by Type
- 9.1.1 Europe Burosumab Revenue by Type (2021-2032)
- 9.1.2 Europe Burosumab Sales by Type (2021-2032)
- 9.1.3 Europe Burosumab Price by Type (2021-2032)
- 9.2 Europe Burosumab Market Size by Application
- 9.2.1 Europe Burosumab Revenue by Application (2021-2032)
- 9.2.2 Europe Burosumab Sales by Application (2021-2032)
- 9.2.3 Europe Burosumab Price by Application (2021-2032)
- 9.3 Europe Burosumab Market Size by Country
- 9.3.1 Europe Burosumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 9.3.2 Europe Burosumab Sales by Country (2021 VS 2025 VS 2032)
- 9.3.3 Europe Burosumab Price by Country (2021-2032)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Netherlands
10 China
- 10.1 China Burosumab Market Size by Type
- 10.1.1 China Burosumab Revenue by Type (2021-2032)
- 10.1.2 China Burosumab Sales by Type (2021-2032)
- 10.1.3 China Burosumab Price by Type (2021-2032)
- 10.2 China Burosumab Market Size by Application
- 10.2.1 China Burosumab Revenue by Application (2021-2032)
- 10.2.2 China Burosumab Sales by Application (2021-2032)
- 10.2.3 China Burosumab Price by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Burosumab Market Size by Type
- 11.1.1 Asia Burosumab Revenue by Type (2021-2032)
- 11.1.2 Asia Burosumab Sales by Type (2021-2032)
- 11.1.3 Asia Burosumab Price by Type (2021-2032)
- 11.2 Asia Burosumab Market Size by Application
- 11.2.1 Asia Burosumab Revenue by Application (2021-2032)
- 11.2.2 Asia Burosumab Sales by Application (2021-2032)
- 11.2.3 Asia Burosumab Price by Application (2021-2032)
- 11.3 Asia Burosumab Market Size by Country
- 11.3.1 Asia Burosumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 11.3.2 Asia Burosumab Sales by Country (2021 VS 2025 VS 2032)
- 11.3.3 Asia Burosumab Price by Country (2021-2032)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Burosumab Market Size by Type
- 12.1.1 SAMEA Burosumab Revenue by Type (2021-2032)
- 12.1.2 SAMEA Burosumab Sales by Type (2021-2032)
- 12.1.3 SAMEA Burosumab Price by Type (2021-2032)
- 12.2 SAMEA Burosumab Market Size by Application
- 12.2.1 SAMEA Burosumab Revenue by Application (2021-2032)
- 12.2.2 SAMEA Burosumab Sales by Application (2021-2032)
- 12.2.3 SAMEA Burosumab Price by Application (2021-2032)
- 12.3 SAMEA Burosumab Market Size by Country
- 12.3.1 SAMEA Burosumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 12.3.2 SAMEA Burosumab Sales by Country (2021 VS 2025 VS 2032)
- 12.3.3 SAMEA Burosumab Price by Country (2021-2032)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
- 13.1 Burosumab Value Chain Analysis
- 13.1.1 Burosumab Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Burosumab Production Mode & Process
- 13.2 Burosumab Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Burosumab Distributors
- 13.2.3 Burosumab Customers
14 Concluding Insights
15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst